Descripción del título
Drug design of zinc-enzyme ...
Brings together functional and structural informationrelevant to the design of drugs targeting zinc enzymes The second most abundant transition element in living organisms, zinc spans all areas of metabolism, with zinc-containing proteins offering both established and potential drug targets. Drug Design of Zinc-Enzyme Inhibitors brings together functional and structural information relevant to these zinc-containing targets. With up-to-date overviews of the latest developments field, this unique and comprehensive text enables readers to understand zinc enzymes and evaluate them
Monografía
monografia Rebiun26712462 https://catalogo.rebiun.org/rebiun/record/Rebiun26712462 m o d | cr -n--------- 090206s2009 njua ob 001 0 eng d 2009005650 1-282-34608-3 9786612346088 0-470-50816-7 0-470-50815-9 CBUC 991013416296206708 CBUC 991010729538606709 MiAaPQ MiAaPQ MiAaPQ eng 615/.19 Drug design of zinc-enzyme inhibitors electronic resource] :] functional, structural, and disease applications edited by Claudiu T. Supuran, Jean-Yves Winum Hoboken, NJ John Wiley & Sons c2009 Hoboken, NJ Hoboken, NJ John Wiley & Sons 1 online resource (1072 p.) 1 online resource (1072 p.) Text txt computer c online resource cr Wiley Series in Drug Discovery and Development v.14 Description based upon print version of record Includes bibliographical references and index DRUG DESIGN OF ZINC-ENZYME INHIBITORS; CONTENTS; PREFACE; CONTRIBUTORS; PART I INTRODUCTION; 1. Introduction to Zinc Enzymes as Drug Targets; PART II DRUG DESIGN OF CARBONIC ANHYDRASE INHIBITORS AND ACTIVATORS; 2. Carbonic Anhydrases as Drug Targets: General Presentation; 3. Zinc Binding Functions in the Design of Carbonic Anhydrase Inhibitors; 4. X-Ray Crystallography of Carbonic Anhydrase Inhibitors and Its Importance in Drug Design; 5. Antiglaucoma Carbonic Anhydrase Inhibitors as Ophthalomologic Drugs 6. Diuretics with Carbonic Anhydrase Inhibitory Activity: Toward Novel Applications for Sulfonamide Drugs7. Drug Design of Carbonic Anhydrase Inhibitors as Anticonvulsant Agents; 8. Carbonic Anhydrase Inhibitors Targeting Cancer: Therapeutic, Immunologic, and Diagnostic Tools Targeting Isoforms IX and XII; 9. Fluorescent- and Spin-Labeled Sulfonamides as Probe for Carbonic Anhydrase IX; 10. Drug Design of Antiobesity Carbonic Anhydrase Inhibitors; 11. Dual Carbonic Anhydrase and Cyclooxygenase-2 Inhibition 12. Advances in the Inhibitory and Structural Investigations on Carbonic Anhydrase Isozymes XIII and XV13. Mechanism and Inhibition of the -Class and -Class Carbonic Anhydrases; 14. Fungal and Nematode Carbonic Anhydrases: Their Inhibition in Drug Design; 15. Crystallographic Studies on Carbonic Anhydrases from Fungal Pathogens for Structure-Assisted Drug Development; 16. Malaria Parasite Carbonic Anhydrase and Its Inhibition in the Development of Novel Therapies of Malaria; 17. Inhibitors of Helicobacter pylori - and -Carbonic Anhydrases as Novel Drugs for Gastroduodenal Diseases 18. QSAR of Carbonic Anhydrase Inhibitors and Their Impact on Drug Design19. Selectivity Issues in the Design of CA Inhibitors; 20. Bicarbonate Transport Metabolons; 21. Metal Complexes of Sulfonamides as Dual Carbonic Anhydrase Inhibitors; 22. Drug Design Studies of Carbonic Anhydrase Activators; PART III DRUG DESIGN OF MATRIX METALLOPROTEINASE INHIBITORS; 23. Matrix Metalloproteinases: An Overview; 24. MMP Inhibitors Based on Earlier Succinimide Strategies: From Early to New Approaches; 25. Drug Design of Sulfonylated MMP Inhibitors; 26. ADAMs and ADAMTs Selective Synthetic Inhibitors 27. QSAR Studies of MMP InhibitorsPART IV DRUG DESIGN OF BACTERIAL ZINC PROTEASE INHIBITORS; 28. Bacterial Zinc Proteases as Orphan Targets; 29. Botulinus Toxin, Tetanus Toxin, and Anthrax Lethal Factor Inhibitors; 30. Clostridium histolyticum Collagenase Inhibitors in the Drug Design; 31. Other Bacterial Zinc Peptidases as Potential Drug Targets; PART V DRUG DESIGN STUDIES OF OTHER ZINC-CONTAINING ENZYMES; 32. Angiotensin Converting Enzyme (ACE) Inhibitors; 33. P-III Metalloproteinase (Leucurolysin-B) from Bothrops leucurus Venom: Isolation and Possible Inhibition 34. CaaX-Protein Prenyltransferase Inhibitors Brings together functional and structural informationrelevant to the design of drugs targeting zinc enzymes The second most abundant transition element in living organisms, zinc spans all areas of metabolism, with zinc-containing proteins offering both established and potential drug targets. Drug Design of Zinc-Enzyme Inhibitors brings together functional and structural information relevant to these zinc-containing targets. With up-to-date overviews of the latest developments field, this unique and comprehensive text enables readers to understand zinc enzymes and evaluate them English Zinc enzymes- Inhibitors- Therapeutic use Drugs- Design Electronic books Supuran, Claudiu T. Wolpé, Sholeh Wolpé, Sholeh 1962-) Winum, Jean-Yves 0-470-27500-6 Wiley Series in Drug Discovery and Development